Sandostatin LAR (long‐acting octreotide acetate) for malignant carcinoid syndrome: a 3‐year experience

Garland, J.; Buscombe, J. R.; Bouvier, Catherine; Bouloux, Pierre‐Marc; Chapman, Michael H.; Chow, A. C.; Reynolds, Nicola; Caplin, Martyn

doi:10.1046/j.1365-2036.2003.01420.x

Cited by 71 publications

(48 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The long-acting analogs of somatostatin, lanreotide (Somatuline ® ; Beaufour Ipsen Pharma, Paris, France) and octreotide (Sandostatin ® ; Novartis, Basel, Switzerland), have been shown to be effective in relieving flushing and diarrhea associated with carcinoid syndrome [6,7,8,9]. Indirect data also suggest that somatostatin analogs may have a beneficial effect on patient survival [3].…”

Section: Introductionmentioning

confidence: 99%

“…Indirect data also suggest that somatostatin analogs may have a beneficial effect on patient survival [3]. Different formulations of these somatostatin analogs are available and, although all seem to be safe and effective, comparative studies in patients with carcinoid syndrome have shown that lanreotide, 30 mg given every 10 days [8], or octreotide, given every 4 weeks [9], are preferred to octreotide given 2–4 times/day. These findings suggest that prolonged-release (PR) formulations are more appropriate for the long-term treatment of the majority of patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide

Ruszniewski

Ish‐Shalom

Wymenga³

et al. 2004

Neuroendocrinology

146

102

View full text Add to dashboard Cite

This 6-month, open, non-controlled, multicenter, dose-titration study evaluated the efficacy and safety of 28-day prolonged-release (PR) lanreotide in the treatment of carcinoid syndrome. Eligible patients had a carcinoid tumor with ≧3 stools/day and/or ≧1 moderate/severe flushing episodes/day. Six treatments of 28-day PR lanreotide were administered by deep subcutaneous injection. The dose for the first two injections was 90 mg. Subsequent doses could be titrated (60, 90, 120 mg) according to symptom response. Seventy-one patients were treated. Flushing decreased from a mean of 3.0 at baseline to 2.3 on day 1, and 2.0 on day 2, with a daily mean of 2.1 for the first week post-treatment (p < 0.05). Diarrhea decreased from a mean of 5.0 at baseline to 4.3 on day 1 (p < 0.05), and 4.5 on day 2, with a daily mean of 4.4 for the first week post-treatment (p < 0.001). Symptom frequency decreased further after the second and third injections, and reached a plateau after the fourth injection. By month 6, flushing and diarrhea had significantly decreased from baseline by a mean of 1.3 and 1.1 episodes/day, respectively (both p ≤ 0.001); 65% of patients with flushing as the target symptom and 18% of diarrhea-target patients achieved ≧50% reduction from baseline. Median urinary 5-hydroxyindoleacetic acid and chromogranin A levels decreased by 24 and 38%, respectively. Treatment was well tolerated. 28-day PR lanreotide was effective in reducing the symptoms and biochemical markers associated with carcinoid syndrome.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide

Ruszniewski

Ish‐Shalom

Wymenga³

et al. 2004

Neuroendocrinology

146

102

View full text Add to dashboard Cite

show abstract

“…The crisis may occur independently, during infection, or as a result of medical procedures: general anaesthesia, endoscopy, tumour biopsy, surgery, embolisation, radioisotope therapy or chemotherapy. Therefore, it is recommended to use somatostatin analogues in the pre-operative period or during surgery on NENs patients [25][26][27].…”

Section: Symptoms Of the Hormonally Active Nens Of The Small Intestinmentioning

confidence: 99%

“…The leading biotherapy method is treatment with SSA (lanreotide and octreotide), which are indicated for the symptomatic therapy of hormonally active NENs of the small intestine. SSA are the preferred treatment option for carcinoid crisis [18,25]. There are ongoing clinical studies on the use of new SSA (pasireotide) in cases of resistance to the standard treatment of carcinoid syndrome [66].…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Bolanowski

Bednarczuk²,

Bobek-Billewicz³

et al. 2014

Endokrynologia Polska

View full text Add to dashboard Cite

We present revised Polish guidelines regarding the management of patients harbouring neuroendocrine neoplasms (NENs) of the small intestine and appendix. The small intestine, especially the ileum, is the most common origin of these neoplasms. Most of them are well differentiated with slow growth. Rarely, they are less differentiated, growing fast with a poor prognosis. Since symptoms can be atypical, the diagnosis is often accidental. Typical symptoms of carcinoid syndrome occur in less than 10% of patients. The most useful laboratory marker is chromogranin A; 5-hydroxyindoleacetic acid is helpful in the monitoring of carcinoid syndrome. Ultrasound, computed tomography, magnetic resonance imaging, colonoscopy, video capsule endoscopy, balloon enteroscopy and somatostatin receptors scintigraphy are used in the visualisation. A histological report is crucial for the proper diagnostics and therapy of NENs, and it has been extensively described. The treatment of choice is surgery, either radical or palliative. Somatostatin analogues are crucial in the pharmacological treatment of the hormonally active and non-active small intestine NENs and NENs of the appendix. Radioisotope therapy is possible in patients with a good expression of somatostatin receptors. Chemotherapy is not effective in general. Everolimus therapy can be applied in patients with generalised NENs of the small intestine in progression and where there has been a failure or an inability to use other treatment options. Finally, we make recommendations regarding the monitoring of patients with NENs of the small intestine and appendix. (6) w mniej niż 10% przypadków. W diagnostyce laboratoryjnej najbardziej przydatne jest oznaczenie stężenia chromograniny A, badanie stężenia kwasu 5-hydroksyindolooctowego jest pomocne w monitorowaniu zespołu rakowiaka. W obrazowaniu stosuje się ultrasonografię, tomografię komputerową, rezonans magnetyczny, kolonoskopię, wideoendoskopię kapsułkową, enteroskopię dwubalonową, scyntygrafię receptorów somatostatynowych. Szczegółowe badanie histologiczne jest kluczowym dla właściwego rozpoznania i leczenia chorych z NEN jelita cienkiego i wyrostka robaczkowego. Leczeniem z wyboru jest postępowanie chirurgiczne, radykalne lub paliatywne. W leczeniu farmakologicznym czynnych i nieczynnych hormonalnie NEN jelita cienkiego i wyrostka robaczkowego podstawowe znaczenie mają analogi somatostatyny. Terapia radioizotopowa u chorych z dobrą ekspresją receptorów somatostatynowych stanowi kolejną opcję terapeutyczną. Chemioterapia jest na ogół nieskuteczna. U pacjentów z rozsianym NEN jelita cienkiego i progresją choroby oraz nieskutecznością innych metod terapii można zastosować ewerolimus. Przedstawiono także zalecenia odnośnie monitorowania chorych z NEN jelita cienkiego i wyrostka robaczkowego. (Endokrynol Pol 2013; 64 (6): 444-493)

show abstract

“…and deep s.c. routes every 28 days. Biochemical response rates with an inhibition of hormone production are seen in 30-70% with symptom control in the majority of patients (Tomassetti et al 1998, 2000, Ricci et al 2000b, Garland et al 2003, Bajetta et al 2006, Toumpanakis et al 2009). Escalation of dose is often required over time for symptom control due to poorly understood 'tachyphylaxis'.…”

Section: Biotherapy Somatostatin Analoguesmentioning

confidence: 99%

Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours

Khan

Caplin²

2011

Endocrine-Related Cancer

View full text Add to dashboard Cite

Patients with neuroendocrine tumours (NETs) are best managed in a specialist centre as part of a multidisciplinary team comprising gastroenterologists, oncologists, endocrinologists, gastrointestinal and hepatopancreaticobiliary surgeons, pathologists, nuclear medicine physicians and technicians, radiologists, specialist nurses, pharmacists, biochemists and dieticians. This should ideally be led by a clinician with experience and interest in NETs. Although the number of medical treatments and clinical trials has increased in the decade, there is still a lack of prospective randomised trials; thus, management is mainly based on limited often single-centre studies, although there are now formal guidelines based on consensus expert opinion. We have outlined the current optimal management of patients with NETs. We have reviewed therapeutic options including surgery, somatostatin analogues and other biotherapies and peptide receptor-targeted therapy. We have discussed the challenge in managing hepatic metastases including hepatic artery embolisation, ablation and orthotopic liver transplant. In addition, we have briefly reviewed the emerging therapies such as the mammalian target of rapamycin and angiogenic inhibitors and the newer somatostatin analogues.

show abstract

Sandostatin LAR (long‐acting octreotide acetate) for malignant carcinoid syndrome: a 3‐year experience

Cited by 71 publications

References 28 publications

Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide

Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide

Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours

Contact Info

Product

Resources

About